Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Combining MBG453 with hypomethylating agents was “extremely well tolerated,” with no high-grade immune-related toxicities. Uma Borate, MD, discusses the safety and preliminary efficacy data.

Advertisement

SHARE